Takaaki Chou

Summary

Affiliation: Niigata Cancer Center Hospital
Country: Japan

Publications

  1. ncbi Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan
    Takaaki Chou
    Department Internal Medicine, Niigata Cancer Center Hospital, 2 15 3 Kawagishimachi, Niigata City, Niigata 951 8566, Japan
    Breast Cancer 12:178-88. 2005
  2. ncbi Multiple myeloma : recent progress in diagnosis and treatment
    Takaaki Chou
    Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
    J Clin Exp Hematop 52:149-59. 2012
  3. doi Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Natsue Igarashi
    Department of Internal Medicine, Niigata Cancer Center Hospital, Chuou ku, Niigata City, Niigata, 951 8566, Japan
    Int J Hematol 92:518-23. 2010
  4. doi Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112
    Takaaki Chou
    Niigata Cancer Center Hospital, Niigata, Japan
    Jpn J Clin Oncol 41:586-9. 2011
  5. doi Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma
    Natsue Igarashi
    Department of Internal Medicine, Niigata Cancer Center Hospital, 2 15 3 Kawagishi cho, Chuou ku, Niigata, Niigata, 951 8566, Japan
    Int J Hematol 90:378-82. 2009
  6. ncbi [Multiple myeloma--recent advances in diagnosis and treatment]
    Takaaki Chou
    Dept of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan
    Gan To Kagaku Ryoho 32:304-8. 2005
  7. ncbi Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
    Yutaka Tokuda
    Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
    Cancer Sci 99:145-51. 2008
  8. ncbi Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma
    Li na Han
    The First Clinical College of Harbin Medical University, Harbin, China
    Int J Hematol 84:174-81. 2006
  9. ncbi Phase II clinical study of cladribine in the treatment of hairy cell leukemia
    Takashi Machii
    Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Hematol 82:230-5. 2005
  10. ncbi Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group
    Chihiro Shimazaki
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620 9566, Japan
    Int J Hematol 81:342-8. 2005

Collaborators

Detail Information

Publications13

  1. ncbi Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan
    Takaaki Chou
    Department Internal Medicine, Niigata Cancer Center Hospital, 2 15 3 Kawagishimachi, Niigata City, Niigata 951 8566, Japan
    Breast Cancer 12:178-88. 2005
    ..The present study was undertaken to evaluate the purging efficacy of autologous mobilized CD34+peripheral stem cells in patients with breast cancer (BRCA) in an advanced stage or relapse...
  2. ncbi Multiple myeloma : recent progress in diagnosis and treatment
    Takaaki Chou
    Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
    J Clin Exp Hematop 52:149-59. 2012
    ..Achievement of a high response rate resulted in the extension of overall survival, but further research and the development of more multimodality therapeutic approaches is warranted to cure this disease...
  3. doi Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Natsue Igarashi
    Department of Internal Medicine, Niigata Cancer Center Hospital, Chuou ku, Niigata City, Niigata, 951 8566, Japan
    Int J Hematol 92:518-23. 2010
    ..Further investigations are required to define how to use new antimyeloma agents for Japanese MM patients...
  4. doi Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112
    Takaaki Chou
    Niigata Cancer Center Hospital, Niigata, Japan
    Jpn J Clin Oncol 41:586-9. 2011
    ..Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma...
  5. doi Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma
    Natsue Igarashi
    Department of Internal Medicine, Niigata Cancer Center Hospital, 2 15 3 Kawagishi cho, Chuou ku, Niigata, Niigata, 951 8566, Japan
    Int J Hematol 90:378-82. 2009
    ..Although more than 50 cases of DCL have been reported, there have been only two reports of DCL developed in MM patients including our case. This rare complication may give some insights into leukemogenesis...
  6. ncbi [Multiple myeloma--recent advances in diagnosis and treatment]
    Takaaki Chou
    Dept of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan
    Gan To Kagaku Ryoho 32:304-8. 2005
    ..Furthermore, novel therapeutic agents, such as thalidomide and other immunomodulatory agents have been extensively investigated. Recent advances in the diagnosis and treatment were reviewed and summarized...
  7. ncbi Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208
    Yutaka Tokuda
    Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259 1193, Japan
    Cancer Sci 99:145-51. 2008
    ..78). Although the prespecified values of the two arms were not so accurate as to allow detection of the observed difference, no advantage of HDC was observed in terms of RFS or overall survival...
  8. ncbi Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma
    Li na Han
    The First Clinical College of Harbin Medical University, Harbin, China
    Int J Hematol 84:174-81. 2006
    ..5% and 78.2%, respectively. These results suggested that LEED, as well as R-LEED, was a safe and feasible high-dose regimen for aggressive and relapsed NHL...
  9. ncbi Phase II clinical study of cladribine in the treatment of hairy cell leukemia
    Takashi Machii
    Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Hematol 82:230-5. 2005
    ..Infections occurred at a high incidence at this time, but all cases could be controlled with appropriate treatment. 2-CdA was surmised to represent a useful therapeutic approach for Japanese patients with HCL...
  10. ncbi Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group
    Chihiro Shimazaki
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620 9566, Japan
    Int J Hematol 81:342-8. 2005
    ..5% and 18.8%, respectively. These observations suggest that RIST is feasible with reliable donor engraftment and relatively low transplantation-related mortality in Japanese MM patients...
  11. ncbi High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma
    Hirokazu Murakami
    School of Health Sciences, Faculty of Medicine, Gunma University, Showa machi, Japan
    Eur J Haematol 73:169-73. 2004
    ..In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients...
  12. ncbi Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma
    Kensei Tobinai
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Int J Hematol 77:512-7. 2003
    ..In conclusion, cladribine is not worthy of further investigation for the treatment of ATL...
  13. ncbi A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma
    Kunihiko Takeyama
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 33:78-85. 2003
    ..However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown...